| Popis: |
A large body of evidence indicates a neuroprotective and neurotrophic function for APPs⍺ not only in vitro, but also when expressed by AAV vectors in vivo such as in APP/PS1 transgenic AD model mice with Aβ-induced pathology. Previously, we could show that APPs⍺ rescued deficits of APP/PS1 in synaptic plasticity and spine density and also reduced plaque deposition. Thus, it is crucial to test a more general applicability of APPs⍺ as a treatment for AD and to assess whether APPs⍺ is also beneficial in mice with tau-induced pathology. |
